The Latest Breaking News from Akebia Therapeutics

Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near

Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference. Erik, Akebia’s chief financial offic

MarketBeat · Jun 5

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga · Nov 4, 2025

Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

Barchart · Mar 31, 2025